Related Experiment Video
Updated: Apr 25, 2026
Platelet-Rich Plasma Lysate for Treatment of Eye Surface Diseases
Published on: August 2, 2022
Subconjunctival injectable platelet-rich fibrin for severe dry eye disease: Preliminary clinical results
Huri Sabur1, Ayse Nur Coban2, Nese Arslan3
1Department of Ophthalmology, Bolu Izzet Baysal State Hospital, Bolu, Turkey. drhurisabur@gmail.com.
Purpose:
To evaluate the prelaminary clinical effects of subconjunctival injectable platelet-rich fibrin (i-PRF) in patients with severe dry eye disease (DED).
Methods:
This study included two groups: an i-PRF group consisting of 28 eyes treated with subconjunctival i-PRF injection and a control group of 32 eyes. The ocular surface disease index (OSDI-12), tear break-up time (TBUT), corneal fluorescein staining (CFS), tear meniscus height (TMH), and tear meniscus area (TMA) were assessed at baseline and during follow-up. Changes in clinical parameters were compared between the groups.
Results:
Baseline demographic characteristics and dry eye parameters were comparable between the groups (all p > 0.05). After three injections, the i-PRF group showed a significantly greater reduction in OSDI-12 and CFS scores, as well as a significant increase in TBUT, compared with the control group. Tear meniscus parameters also improved in the i-PRF group, with TMH increasing from 145.9 ± 28.5 (143.0) to 254.3 ± 35.3 (258.5) µm and TMA from 0.015 ± 0.004 (0.016) to 0.043 ± 0.005(0.043) mm².
Conclusion:
Subconjunctival i-PRF injection was associated with improvements in both subjective symptoms and objective ocular surface parameters in patients with severe DED. These preliminary results suggest that i-PRF may be a promising adjunctive treatment option for patients refractory to conventional therapies. Further prospective controlled studies with longer follow-up are needed to confirm its efficacy and durability.
